Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus
1. 请及时下载文件确认是否正确, 系统将在 2026-02-09 19:14:42 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1007/s12325-025-03299-0
文献链接: https://link.springer.com/10.1007/s12325-025-03299-0
其他信息:
出版社: Springer Science and Business Media LLC
作者: Cristina Arriens; Eric F. Morand; Anca D. Askanase; Richard Furie; Ronald F. van Vollenhoven; Yoshiya Tanaka; Kevin Connors; Monica Davey; Kimberly Young; Giovanni Franchin; Richard Meier; Vaishali Shah; Carolina Leite de Oliveria; Coburn Hobar
全文下载地址: https://link.springer.com/content/pdf/10.1007/s12325-025-03299-0.pdf
